ALK ‐rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors
Genes, Chromosomes and Cancer · 2023-02 · 62 (2) · 75-84
DOI: 10.1002/gcc.23097 ↗Kurz gefasst
Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 07.10.2022. Verfasst von Josephine K Dermawan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Anaplastic lymphoma kinase (ALK) fusions are oncogenic drivers in diverse cancer types. Although well established in inflammatory myofibroblastic tumor (IMT) and epithelioid fibrous histiocytoma (EFH), ALK rearrangements also occur in the emerging family of kinase fusion‐positive mesenchymal neoplasms. We investigated 9 ALK‐rearranged mesenchymal neoplasms (exclusive of IMT and EFH) arising in 6 males and 3 females with a wide age range of 10 to 78 years old (median 42 years). Tumors involved superficial and deep soft tissue (6) and viscera (3). Three were myxoid or collagenous low‐grade paucicellular tumors with haphazardly arranged spindled cells. Three were cellular tumors with spindled cells in intersecting short fascicles or solid sheets. Three cases consisted of uniform epithelioid cells arranged in nests or solid sheets, with prominent mitotic activity and necrosis. Band‐like stromal hyalinization was present in 6 cases. All tumors expressed ALK; four were positive for S100 and five were positive for CD34, while all were negative for SOX10. By targeted RNA sequencing, the breakpoints involved ALK exon 20; the 5′ partners included KLC1 , EML4 , DCTN1 , PLEKHH2 , TIMP3 , HMBOX1 , and FMR1 . All but two patients presented with localized disease. One patient had distant lung metastases; another had diffuse pleural involvement. Of the six cases with treatment information, five were surgically excised [one also received neoadjuvant radiation therapy (RT)], and one received RT and an ALK inhibitor. Of the four patients with follow‐up (median 5.5 months), one remained alive with stable disease and three were alive without disease. We expand the clinicopathologic spectrum of ALK ‐fused mesenchymal neoplasms, including a low‐grade malignant peripheral nerve sheath tumor‐like subset and another subset characterized by epithelioid and high‐grade morphology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Josephine K Dermawan, Narasimhan P Agaram, Brendan C Dickson, Cristina R Antonescu
Förderung
- NCI NIH HHS
Zitieren
APA
Dermawan, J. K., DiNapoli, S. E., Mullaney, K. A., Sukhadia, P., Agaram, N. P., Dickson, B. C., & Antonescu, C. R. (2023). ALK ‐rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors. Genes, Chromosomes and Cancer, 62(2), 75-84. https://doi.org/10.1002/gcc.23097
Vancouver
Dermawan JK, DiNapoli SE, Mullaney KA, Sukhadia P, Agaram NP, Dickson BC, et al. ALK ‐rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors. Genes, Chromosomes and Cancer. 2023;62(2):75-84. doi:10.1002/gcc.23097
BibTeX
@article{Dermawan2023,
author = {Dermawan, Josephine K and DiNapoli, Sara E and Mullaney, Kerry A and Sukhadia, Purvil and Agaram, Narasimhan P and Dickson, Brendan C and Antonescu, Cristina R},
title = {ALK ‐rearranged Mesenchymal Neoplasms: A Report of 9 cases Further Expanding the Clinicopathologic Spectrum of Emerging Kinase Fusion Positive Group of Tumors},
journal = {Genes, Chromosomes and Cancer},
year = {2023},
volume = {62},
number = {2},
pages = {75--84},
doi = {10.1002/gcc.23097}
}
EUVIMED